Association Between LRG and Histologic Remission in Ulcerative Colitis

Launched by SHOWA INAN GENERAL HOSPITAL · Apr 15, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a substance in the blood called leucine-rich α 2-glycoprotein (LRG) to see if it can help predict when patients with ulcerative colitis (UC) are in a state of histologic remission. Histologic remission means that the tissue in the colon looks normal under a microscope, even if patients aren’t experiencing symptoms. If you are currently experiencing active ulcerative colitis, you may be eligible to participate in this study, which is open to people of all ages.

Participants in the trial will have their blood tested to measure LRG levels, and if those levels suggest remission, they will undergo a colonoscopy—a procedure that allows doctors to look at the inside of the colon. This study is currently recruiting participants, and it aims to provide important information about how LRG can be used as a tool to monitor ulcerative colitis. If you're interested in contributing to this research, it might be a good opportunity to help improve care for others with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • active UC patients
• Exclusion Criteria:
• • None